



Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



Date: 16 May 2026

Ref. No.: TCPCL/SEC/2026-27/00009

To,
The General Manager,
Corporate relationship department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001
Scrip Code: 543321

The Manager,
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex, Bandra(E),
Mumbai-400 051
Scrip Symbol: TATVA

Subject: Intimation under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "SEBI Listing Regulations"), we wish to inform you that the Board of Directors of Tatva Chintan Pharma Chem Limited (the "Company") in its meeting held today i.e. 16 May 2026 have *inter-alia*, approved and taken on record the following items:

1. Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended 31 March 2026. In this regard, please find enclosed:
 - i. Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended 31 March 2026;
 - ii. Auditors' Report (Standalone and Consolidated) for the quarter and financial year ended 31 March 2026; and
 - iii. Declaration pursuant to regulation 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended.
2. The Board recommended a Final Dividend of Rs. 2/- (20%) per equity share of Rs. 10/- each fully paid (subject to deduction of tax, if any) on the equity share capital of Rs. 23,39,20,550/- (2,33,92,055 equity shares of Rs. 10/- each) for the financial year 2025-26. This shall be paid subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.
3. The Board, based on the recommendation of the Audit Committee, has approved the appointment of M/s. Zarna Thakar & Associates, Cost Accountants, as a Cost Auditor of the Company, to audit the cost records of the Company for the financial year 2026-27 and recommended the remuneration for the approval of the shareholders at the ensuing Annual General Meeting of the Company.
4. The Board, based on the recommendation of the Audit Committee, has approved the appointment of RSM Astute Consultech Private Limited as Internal Auditor of the Company for the financial year 2026-27.

Disclosure under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on 11 July 2023 and last updated on 30 January 2026 for the matters mentioned at Item 3 and 4 above, is enclosed herewith as "**Annexure A**".

Registered Office and Factory : Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.

Dahej SEZ Unit : Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.

Corporate Office and R & D Center (DSIR Approved) : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.

Telephone No. : +91 75748 48533 / 34 **Fax :** +91 265 263 8533 **E-mail :** cs@tatvachintan.com **Website :** www.tatvachintan.com



Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



The above information shall be made available on the website of the Company at www.tatvachintan.com.

The Meeting commenced at 12:30 P.M. and concluded at 03:05 P.M.

Kindly take above intimation on your record and oblige.

Thanking you,

Yours faithfully,

For Tatva Chintan Pharma Chem Limited

Ishwar Nayi
Company Secretary and Compliance Officer
M. No.: A37444

Encl.: As above



Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



Disclosure under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on 11 July 2023 and last updated on 30 January 2026.

Annexure A

Sr. No.	Particulars	M/s. Zarna Thakar & Associates	RSM Astute Consultech Private Limited
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of M/s. Zarna Thakar & Associates, Cost Accountants, as a Cost Auditor of the Company.	Appointment of RSM Astute Consultech Private Limited as Internal Auditor of the Company.
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	Appointment in the Board Meeting held on 16 May 2026, to audit the cost records of the Company for the financial year 2026-27.	Appointment in the Board Meeting held on 16 May 2026, as Internal Auditor of the Company for the financial year 2026-27.
3.	Brief profile (in case of appointment)	M/s. Zarna Thakar & Associates is a leading Cost & Management Accounting firm with 10+ years of experience in Cost Audit, Product Costing, Internal Controls, and Management Information Systems (MIS). The firm has a Pan-India presence and has successfully conducted cost audits for 100+ companies across industries including chemicals, pharmaceuticals, engineering, textiles, mining, and plastics. M/s. Zarna Thakar & Associates specialize in Cost Audit under Section 148 of the Companies Act, Physical Stock Verification, Fixed Asset Verification & Tagging, SAP CO Module consulting, and profitability analysis. Their expertise lies in designing effective costing systems, SKU-level product costing, variance analysis, and business process improvements that support strategic decision-making.	RSM Astute Consulting Group along with its affiliates (together referred as 'RSM India') ranks amongst India's top 6 audit, tax and consulting groups and is part of RSM International, with Pan-India presence with offices in 14 key cities and provides services in various areas like Internal Audits & Risk Advisory, Corporate Tax & GST, IT Systems Assurance & Solutions and Operations Consulting etc.
4.	Disclosure of Relationship between Directors (in case of appointment as a Director)	Not Applicable	Not Applicable

Registered Office and Factory : Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.

Dahej SEZ Unit : Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.

Corporate Office and R & D Center (DSIR Approved) : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.

Telephone No. : +91 75748 48533 / 34 **Fax :** +91 265 263 8533 **E-mail :** cs@tatvachintan.com **Website :** www.tatvachintan.com

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Tatva Chintan Pharma Chem Limited

Report on the Audit of Consolidated Annual Financials Results

Opinion

1. We have audited the accompanying Consolidated Annual Financial Results of Tatva Chintan Pharma Chem Limited (hereinafter referred to as "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group") for the year ended March 31, 2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. In our opinion and to the best of our information and according to the explanations given to us, the Consolidated Annual Financial Results for the year ended March 31, 2026:
 - i. includes the annual financial results of Tatva Chintan USA Inc. and Tatva Chintan Europe B.V. (Subsidiaries);
 - ii. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
 - iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income and other financial information of the Group for the year ended March 31, 2026.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in Auditor's Responsibilities for the audit of the Consolidated Annual Financial Results section below of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Annual Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the Consolidated Annual Financial Results.



Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

4. These Consolidated Annual Financial Results have been prepared on the basis of the consolidated financial statements. The Holding Company's Management and Board of Directors are responsible for the preparation and presentation of these Consolidated Annual Financial Results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each companies and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Annual Financial Results by the Management and the Board of Directors of the Holding Company, as aforesaid.
5. In preparing the Consolidated Annual Financial Results, the respective Management and Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective company or to cease operations, or has no realistic alternative but to do so.
6. The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of their respective companies.

Auditor's Responsibilities for the audit of the Consolidated Annual Financial Results

7. Our objectives are to obtain reasonable assurance about whether the Consolidated Annual Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Annual Financial Results.



8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the Consolidated Annual Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Management and Board of Directors.
 - Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Annual Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the Consolidated Annual Financial Results, including the disclosures, and whether the Consolidated Annual Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
 - Obtain sufficient appropriate audit evidence regarding the Consolidated Annual Financial Results of the entities within the Group to express an opinion on the Consolidated Annual Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of all entities included in the Consolidated Annual Financial Results. We remain solely responsible for our audit opinion.
9. We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Annual Financial Results of which we are independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
11. We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by SEBI under Regulations 33(8) of the Listing Regulations, as amended, to the extent applicable.



Other Matters

12. The Consolidated Annual Financial Results include the results for the quarter ended March 31, 2026, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which were subjected to limited review by us.

Our report on the Consolidated Annual Financial Results is not modified in respect of this matter.

For NDJ & Co.

Chartered Accountants

Firm's Registration Number: 136345W

Basant.



CA Basant Chandak
Partner

Membership No.: 434585

UDIN: 26434585WNMWSR3102

Date: May 16, 2026

Place: Vadodara



Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
 Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Consolidated Statement of Financial Results

for the quarter and year ended 31 March 2026

(Currency: Indian Rupees in million, except per share data)

Sr. No.	Particulars	Quarter ended			Year ended	
		31.03.2026 (Unaudited)	31.12.2025 (Unaudited)	31.03.2025 (Unaudited)	31.03.2026 (Audited)	31.03.2025 (Audited)
	Income					
1	Revenue from operations	1,341.44	1,313.34	1,078.64	5,058.58	3,827.14
2	Other income	(3.48)	17.34	7.22	35.49	23.15
3	Total income (1+2)	1,337.96	1,330.68	1,085.86	5,094.07	3,850.29
	Expenses					
	Cost of materials consumed	672.61	696.13	479.16	2,627.50	1,737.64
	Purchases of stock-in-trade	22.43	17.24	7.75	64.94	29.80
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(133.18)	(161.92)	89.94	(447.05)	221.97
	Employee benefits expense	170.74	168.24	140.48	629.32	529.16
	Finance costs	14.38	4.93	3.88	28.51	12.90
	Depreciation and amortisation expenses	97.55	90.68	72.58	368.47	276.59
	Other expenses	327.56	338.80	271.80	1,252.29	966.44
4	Total expenses	1,172.09	1,154.10	1,065.59	4,523.98	3,774.50
5	Profit/(loss) before exceptional items and tax (3-4)	165.87	176.58	20.27	570.09	75.79
6	Exceptional items	-	-	-	-	-
7	Profit/(loss) before tax (5-6)	165.87	176.58	20.27	570.09	75.79
	Tax expenses/(benefits)					
	Current tax	30.14	46.12	6.70	119.68	15.47
	Deferred tax	32.52	(21.19)	3.27	29.87	3.19
8	Total tax expenses/(benefits)	62.66	24.93	9.97	149.55	18.66
9	Profit for the period/year (7-8)	103.21	151.65	10.30	420.54	57.13
	Other comprehensive income/(expense)					
	Items that will not be reclassified to profit or loss	2.01	2.40	(0.80)	2.45	(3.06)
	Income tax relating to items that will not be reclassified to profit or loss	(0.58)	(0.70)	0.23	(0.71)	0.89
	Items that will be reclassified to profit or loss	12.59	3.13	1.98	30.46	9.24
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
10	Other comprehensive income/(expense) for the period/year, net of tax	14.02	4.83	1.41	32.20	7.07
11	Total comprehensive income for the period/year (9+10)	117.23	156.48	11.71	452.74	64.20
12	Profit for the period/year attributable to:					
	- Owners of the parent	103.21	151.65	10.30	420.54	57.13
	- Non controlling interests	-	-	-	-	-
		103.21	151.65	10.30	420.54	57.13
13	Other comprehensive income/(expense) for the period/year attributable to:					
	- Owners of the parent	14.02	4.83	1.41	32.20	7.07
	- Non controlling interests	-	-	-	-	-
		14.02	4.83	1.41	32.20	7.07
14	Total comprehensive income for the period/year attributable to:					
	- Owners of the parent	117.23	156.48	11.71	452.74	64.20
	- Non controlling interests	-	-	-	-	-
		117.23	156.48	11.71	452.74	64.20
15	Earnings per share (Face value of Rs 10/- each) (not annualised)					
	- Basic	4.41	6.49	0.44	17.98	2.44
	- Diluted	4.41	6.49	0.44	17.98	2.44
16	Paid - up equity share capital (Face value of Rs 10/- each)	233.92	233.92	233.92	233.92	233.92
17	Other equity excluding revaluation reserve				7,583.67	7,154.32

Notes forming part of the consolidated statement of financial results





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Consolidated Statement of Assets and Liabilities

as at 31 March 2026

(Currency: Indian Rupees in million)

Particulars	31.03.2026 (Audited)	31.03.2025 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	5,741.83	4,959.96
Right-of-use assets	299.64	295.56
Capital work-in-progress	233.48	215.35
Other intangible assets	52.56	31.24
Intangible assets under development	15.70	27.75
Financial assets		
i) Investments	40.00	-
ii) Other financial assets	49.52	42.82
Deferred tax assets (net)	95.67	126.24
Other non-current assets	13.42	11.12
Total non-current assets	6,541.82	5,710.04
Current assets		
Inventories	1,960.74	1,339.54
Financial assets		
i) Trade receivables	1,190.31	895.49
ii) Cash and cash equivalents	57.64	113.74
iii) Bank balances other than cash and cash equivalents	30.27	27.22
iv) Loans	2.65	2.37
v) Other financial assets	3.55	11.01
Current tax assets (net)	10.53	69.70
Other current assets	239.43	193.38
Total current assets	3,495.12	2,652.45
Total assets	10,036.94	8,362.49
EQUITY AND LIABILITIES		
Equity		
Equity share capital	233.92	233.92
Other equity	7,583.67	7,154.32
Equity attributable to owners	7,817.59	7,388.24
Non-controlling interests	-	-
Total equity	7,817.59	7,388.24
Liabilities		
Non-current liabilities		
Financial liabilities		
i) Borrowings	50.10	-
Employee benefit obligations	25.89	13.98
Other non-current liabilities	12.01	-
Total non-current liabilities	88.00	13.98
Current liabilities		
Financial liabilities		
i) Borrowings	1,153.63	363.88
ii) Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	174.77	108.21
(b) total outstanding dues of creditors other than above	407.69	218.68
iii) Other financial liabilities	126.75	54.69
Other current liabilities	259.79	190.41
Provisions	5.55	4.24
Current tax liabilities (net)	3.17	20.16
Total current liabilities	2,131.35	960.27
Total equity and liabilities	10,036.94	8,362.49

Notes forming part of the consolidated financial results





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002

Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Consolidated Statement of Cash Flows

for the year ended 31 March 2026

(Currency: Indian Rupees in million)

Particulars		31.03.2026 (Audited)	31.03.2025 (Audited)
A. Cash flows from operating activities:			
Profit before tax	(i)	570.09	75.79
Adjustments to reconcile profit:			
Finance costs		28.51	12.90
Depreciation and amortisation expenses		368.47	276.59
Unrealised foreign exchange loss/(gain) (net)		20.25	(0.24)
Interest income		(7.13)	(4.87)
Net gain on sale of current investments		(0.06)	(0.75)
Other non-cash items		30.80	9.47
Total adjustments to reconcile profit	(ii)	440.84	293.10
Operating profit before working capital changes	(iii) = (i) + (ii)	1,010.93	368.89
Changes in working capital:			
(Increase)/decrease in inventories		(621.20)	188.11
(Increase)/decrease in trade receivables		(215.03)	(221.83)
Decrease/(increase) in other non-current financial assets		(2.95)	(0.22)
Decrease/(increase) in other current financial assets		6.33	0.63
Decrease/(increase) in other non-current assets		(2.30)	(2.80)
Decrease/(increase) in other current assets		(35.11)	8.48
Increase/(decrease) in trade payables		196.95	(131.04)
(Decrease)/increase in other current financial liabilities		(2.72)	(0.24)
(Decrease)/increase in other current liabilities		43.57	81.48
(Decrease)/increase in non-current provisions		11.90	0.64
(Decrease)/increase in current provisions		1.31	0.62
Total changes in working capital	(iv)	(619.25)	(76.17)
Cash generated from operating activities	(v) = (iii) + (iv)	391.68	292.72
Less: Taxes paid (Net of refund)	(vi)	(76.79)	(44.98)
Net cash generated from operating activities	(A) = (v) + (vi)	314.89	247.74
B. Cash flows from investing activities:			
Purchase of property, plant and equipment (including right-of-use assets, capital work-in-progress, other intangible assets and intangible assets under development.)		(1,137.74)	(762.72)
Government grant received for capital asset		14.20	-
Proceeds from sale of property, plant and equipment		3.58	1.39
(Increase)/decrease in deposits with banks		(6.80)	2.65
Purchase of Investment (Non current)		(40.00)	-
Purchase of current investment		(40.00)	-
Proceeds from sale of current investments		40.06	101.27
Interest income		8.28	3.57
Cash (used in) investing activities	(B)	(1,158.42)	(653.84)





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Consolidated Statement of Cash Flows

for the year ended 31 March 2026

(Currency: Indian Rupees in million)

Particulars	31.03.2026 (Audited)	31.03.2025 (Audited)
C. Cash flows from financing activities:		
Dividend paid	(23.39)	(46.78)
Proceeds from long-term borrowings	60.40	-
Repayment of long-term borrowings	(6.38)	(32.19)
Net proceeds from short-term borrowings	785.84	257.49
Decrease / (increase) in loans to employees	(0.28)	0.04
Interest paid	(26.87)	(12.63)
Cash generated from financing activities (C)	789.32	165.93
Net decrease in cash and cash equivalents D=(A+B+C)	(54.21)	(240.17)
Cash and cash equivalents at the beginning of the year (E)	113.74	353.04
Effect of exchange rate changes on cash and cash equivalents (F)	(1.89)	0.87
Cash and cash equivalents at the end of the year (D+E+F)	57.64	113.74
Components of cash and cash equivalents:		
Cash on hand	0.82	0.82
Balances with banks:		
- in current accounts	8.02	7.84
- in current accounts (foreign currency)	42.26	20.15
- in cash credit accounts (surplus)	0.01	0.01
- in EEFC current accounts	1.61	80.35
- in deposits with original maturity of less than 3 months	4.92	4.57
Balance as per statement of cash flows	57.64	113.74

Notes forming part of the consolidated statement of financial results

1- 8





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Notes forming part of the Consolidated Statement of Financial Results

for the quarter and year ended 31 March 2026


(Currency: Indian Rupees in million)

- In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this Statement of Consolidated Financial Results for the quarter and year ended 31 March 2026 ("Consolidated Financial Results") of Tatva Chintan Pharma Chem Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group" or "the Company") has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 16 May 2026.
- The Consolidated Financial Results of the Company for the year ended 31 March 2026 has been subjected to audit by the statutory auditors of the Company, who has expressed an unmodified opinion.
- The Consolidated Financial Results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- The Board of Directors has recommended a final dividend of 20% (Rs 2/- per equity share of face value Rs 10 each) for the financial year ended 31 March 2026 which is subject to the approval of shareholders at the ensuing Annual General Meeting.
- The Company has only one reportable business segment i.e. specialty chemicals, accordingly segment disclosure is not required as per Ind AS 108 - Operating Segments.
- Key numbers of Standalone Statement of Financial Results for the quarter and year ended 31 March 2026:

Sr. no.	Particulars	Quarter ended			Year ended	
		31.03.2026 (Unaudited)	31.12.2025 (Unaudited)	31.03.2025 (Unaudited)	31.03.2026 (Audited)	31.03.2025 (Audited)
1.	Total income from operations (Net)	1,326.65	1,385.88	1,076.48	4,962.96	3,664.15
2.	Net profit/(loss) before tax (before exceptional items)	149.75	187.92	15.54	531.65	4.61
3.	Net profit/(loss) before tax (after exceptional items)	149.75	187.92	15.54	531.65	4.61
4.	Net profit/(loss) after tax	90.23	159.84	10.95	390.82	3.27
5.	Total comprehensive income/(expense)	91.66	161.54	10.38	392.56	1.10

- The Consolidated Financial Results of the Company shall be available on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the equity shares of the Company are listed and also on Company's website www.tatvachintan.com.
- Figures for the previous periods/year have been reclassified/rearranged/regrouped to conform to classification of current period, wherever necessary.

For and on behalf of the Board of Directors of
Tatva Chintan Pharma Chem Limited


Chintan N. Shah
Chairman and Managing Director
DIN : 00183618
Place : Vadodara, Gujarat, India
Date : 16 May 2026



INDEPENDENT AUDITOR'S REPORT

To the Board of Directors of Tatva Chintan Pharma Chem Limited

Report on the Audit of Standalone Annual Financials Results

Opinion

1. We have audited the accompanying standalone annual financial results of Tatva Chintan Pharma Chem Limited (hereinafter referred to as the "Company") for the year ended March 31, 2026, attached herewith, being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:
 - (i) are presented in accordance with the requirements of Regulations 33 of the Listing Regulations in this regard; and
 - (ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards and other accounting principles generally accepted in India, of net profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2026.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone annual financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

4. These standalone annual financial results have been prepared on the basis of the standalone annual financial statements. The Company's Management and Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone annual financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the company in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and

prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

5. In preparing the standalone annual financial results, the Management and Board of Directors of the Company are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors of the Company are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the Standalone Annual Financial Results

7. Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.
8. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



- Conclude on the appropriateness of Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance of the Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

11. The standalone annual financial results include the results for the quarter ended March 31, 2026, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which were subjected to limited review by us.

Our report on the standalone annual financial results is not modified in respect of this matter.

12. The standalone annual financial results dealt with by this report have been prepared for the express purpose of filing with National Stock Exchange of India Limited and BSE Limited. These results are based on and should be read with the audited standalone financial statements of the Company for the year ended March 31, 2026 on which we issued an unmodified audit opinion vide our report dated May 16, 2026.

For NDJ & Co.

Chartered Accountants

Firm's Registration Number: 136345W

Basant

CA Basant Chandak

Partner

Membership No.: 434585

UDIN: 26434585AXQSYG1395

Date: May 16, 2026

Place: Vadodara





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002

Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Standalone Statement of Financial Results

for the quarter and year ended 31 March 2026

(Currency: Indian Rupees in million, except per share data)

Sr. No.	Particulars	Quarter ended			Year ended	
		31.03.2026 (Unaudited)	31.12.2025 (Unaudited)	31.03.2025 (Unaudited)	31.03.2026 (Audited)	31.03.2025 (Audited)
	Income					
1	Revenue from operations	1,326.65	1,385.88	1,076.48	4,962.96	3,664.15
2	Other income	(3.69)	17.34	12.95	35.28	35.61
3	Total income (1+2)	1,322.96	1,403.22	1,089.43	4,998.24	3,699.76
	Expenses					
	Cost of materials consumed	672.60	696.13	479.16	2,627.49	1,737.64
	Purchases of stock-in-trade	-	-	-	-	-
	Changes in inventories of finished goods and work-in-progress	(70.82)	(54.68)	125.00	(317.92)	239.01
	Employee benefits expense	170.75	168.24	140.48	629.32	529.16
	Finance costs	14.38	4.93	3.88	28.51	12.90
	Depreciation and amortisation expense	97.53	90.67	72.56	368.42	276.54
	Other expenses	288.77	310.01	252.81	1,130.77	899.90
4	Total expenses	1,173.21	1,215.30	1,073.89	4,466.59	3,695.15
5	Profit before exceptional items and tax (3-4)	149.75	187.92	15.54	531.65	4.61
6	Exceptional items	-	-	-	-	-
7	Profit before tax (5-6)	149.75	187.92	15.54	531.65	4.61
	Tax expenses/(benefits)					
	Current tax	25.70	41.42	(0.14)	100.67	0.02
	Deferred tax	33.82	(13.34)	4.73	40.16	1.32
8	Total tax expenses	59.52	28.08	4.59	140.83	1.34
9	Profit for the period/year (7-8)	90.23	159.84	10.95	390.82	3.27
	Other comprehensive income/(expenses)					
	Items that will not be reclassified to profit or loss	2.01	2.40	(0.80)	2.45	(3.06)
	Income tax relating to items that will not be reclassified to profit or loss	(0.58)	(0.70)	0.23	(0.71)	0.89
10	Other comprehensive income/(expenses) for the period/year, net of tax	1.43	1.70	(0.57)	1.74	(2.17)
11	Total comprehensive income for the period/year (9+10)	91.66	161.54	10.38	392.56	1.10
12	Earnings per share (Face value of Rs 10/- each) (not annualised)					
	- Basic	3.86	6.84	0.47	16.71	0.14
	- Diluted	3.86	6.84	0.47	16.71	0.14
13	Paid - up equity share capital (Face value of Rs 10/- each)	233.92	233.92	233.92	233.92	233.92
14	Other equity excluding revaluation reserve				7,348.37	6,979.20

Notes forming part of the standalone statement of financial results

1-7





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Standalone Statement of Assets and Liabilities

as at 31 March 2026

(Currency: Indian Rupees in million)

Particulars	31.03.2026 (Audited)	31.03.2025 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	5,741.66	4,959.80
Right-of-use assets	299.64	295.56
Capital work-in-progress	233.48	215.35
Other intangible assets	52.56	31.24
Intangible assets under development	15.70	27.75
Financial assets		
i) Investments	46.67	6.67
ii) Other financial assets	49.52	42.82
Deferred tax assets (net)	81.68	122.54
Other non-current assets	13.42	11.12
Total non-current assets	6,534.33	5,712.85
Current assets		
Inventories	1,694.66	1,233.01
Financial assets		
i) Trade receivables	1,437.19	903.29
ii) Cash and cash equivalents	14.70	92.05
iii) Bank balances other than cash and cash equivalents	30.28	27.22
iv) Loans	2.65	2.37
v) Other financial assets	3.55	11.01
Current tax assets (net)	0.53	54.82
Other current assets	235.93	191.39
Total current assets	3,419.49	2,515.16
Total assets	9,953.82	8,228.01
EQUITY AND LIABILITIES		
Equity		
Equity share capital	233.92	233.92
Other equity	7,348.37	6,979.20
Total equity	7,582.29	7,213.12
Liabilities		
Non-current liabilities		
Financial liabilities		
i) Borrowings	50.10	-
Employee benefit obligations	25.89	13.98
Other non-current liabilities	12.01	-
Total non-current liabilities	88.00	13.98
Current liabilities		
Financial liabilities		
i) Borrowings	1,153.63	363.88
ii) Trade payables		
(a) total outstanding dues of micro enterprises and small enterprises	174.77	108.21
(b) total outstanding dues of creditors other than above	398.20	214.88
iii) Other financial liabilities	126.75	54.69
Other current liabilities	421.46	255.01
Provisions	5.55	4.24
Current tax liabilities (net)	3.17	-
Total current liabilities	2,283.53	1,000.91
Total equity and liabilities	9,953.82	8,228.01

Notes forming part of the standalone statement of financial results





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Standalone Statement of Cash Flows

for the year ended 31 March 2026

(Currency: Indian Rupees in million)

Particulars		31.03.2026 (Audited)	31.03.2025 (Audited)
A. Cash flows from operating activities:			
Profit before tax	(i)	531.65	4.61
Adjustments to reconcile profit:			
Finance costs		28.51	12.90
Depreciation and amortisation expenses		368.42	276.54
Unrealised foreign exchange loss/(gain) (net)		22.65	(0.67)
Interest income		(7.13)	(4.87)
Net gain on sale of current investments		(0.06)	(0.75)
Other non-cash items		0.53	0.23
Total adjustments to reconcile profit	(ii)	412.92	283.38
Operating profit before working capital changes	(iii) = (i) + (ii)	944.57	287.99
Changes in working capital:			
(Increase)/decrease in inventories		(461.63)	208.08
(Increase) in trade receivables		(460.89)	(242.53)
(Increase) in other non-current financial assets		(2.95)	(0.22)
Decrease in other current financial assets		6.33	0.64
(Increase) in other non-current assets		(2.31)	(2.80)
(Increase)/(decrease) in other current assets		(33.74)	102.18
Increase/(decrease) in trade payables		193.74	(129.06)
(Decrease) in other current financial liabilities		(2.72)	(0.24)
(Decrease)/increase in other current liabilities		140.39	59.15
(Decrease)/increase in non-current provisions		11.90	0.64
(Decrease)/increase in current provisions		1.31	0.62
Total changes in working capital	(iv)	(610.57)	(3.54)
Cash generated from operating activities	(v) = (iii) + (iv)	334.00	284.45
Less: Taxes paid (net of refund)	(vi)	(42.35)	(44.37)
Net cash generated from operating activities	(A) = (v) + (vi)	291.65	240.08
B. Cash flows from investing activities:			
Purchase of property, plant and equipment (including right-of-use assets, capital work-in-progress, other intangible assets and intangible assets under development.)		(1,137.65)	(762.70)
Government grant received for capital asset		14.20	-
Proceeds from sale of property, plant and equipment		3.58	1.39
(Increase)/decrease in deposits with banks		(6.80)	2.65
Purchase of Investment (Non current)		(40.00)	-
Purchase of Investment (Current)		(40.00)	-
Proceeds from sale of current investments		40.06	101.27
Interest income		8.28	3.57
Cash (used in) investing activities	(B)	(1,158.33)	(653.82)





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Standalone Statement of Cash Flows

for the year ended 31 March 2026

(Currency: Indian Rupees in million)

Particulars	31.03.2026 (Audited)	31.03.2025 (Audited)
C. Cash flows from financing activities:		
Dividend paid	(23.39)	(46.78)
Proceeds from Non-current borrowings	60.40	-
Net proceeds from long-term borrowings	(6.38)	(32.19)
Net proceeds from short-term borrowings	785.84	257.49
Decrease / (increase) in loans to employees	(0.28)	0.04
Interest paid	(26.87)	(12.63)
Cash generated from financing activities (C)	789.32	165.93
Net decrease in cash and cash equivalents D=(A+B+C)	(77.36)	(247.81)
Cash and cash equivalents at the beginning of the year (E)	92.05	339.86
Effect of exchange rate changes on cash and cash equivalents (F)	0.01	(0.00)
Cash and cash equivalents at the end of the year (D+E+F)	14.70	92.05
Components of cash and cash equivalents:		
Cash on hand	0.82	0.82
Balances with banks:		
- in current accounts	7.34	6.30
- in cash credit accounts (surplus)	0.01	0.01
- in EEFC current accounts	1.61	80.35
- in deposits with original maturity of less than 3 months	4.92	4.57
Balance as per statement of cash flows	14.70	92.05

Notes forming part of the standalone statement of financial results

1- 7





Tatva Chintan Pharma Chem Limited

CIN: L24232GJ1996PLC029894

Registered office: Plot no. 502/17, GIDC Estate, Ankleshwar, Bharuch, Gujarat – 393 002
Website : www.tatvachintan.com, E-mail : cs@tatvachintan.com, Tel. no.: +91 75748 48533

Notes forming part of the Standalone Statement of Financial Results

for the quarter and year ended 31 March 2026

(Currency: Indian Rupees in million)

- 1 In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this Statement of Standalone Financial Results for the quarter and year ended 31 March 2026 ("Standalone Financial Results") of Tatva Chintan Pharma Chem Limited ("the Company") has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 16 May 2026.
- 2 The Standalone Financial Results of the Company for the year ended 31 March 2026, have been subjected to audit by the statutory auditors of the Company, who have expressed an unmodified opinion.
- 3 The Standalone Financial Results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 4 The Board of Directors has recommended a final dividend of 20% (Rs 2/- per equity share of face value Rs 10 each) for the financial year ended 31 March 2026, which is subject to the approval of shareholders at the ensuing Annual General Meeting.
- 5 The Company has only one reportable business segment i.e. specialty chemicals, accordingly segment disclosure is not required as per Ind AS 108 - Operating Segments.
- 6 The Standalone Financial Results of the Company shall be available on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the equity shares of the Company are listed and also on Company's website www.tatvachintan.com.
- 7 Figures for the previous periods/year have been reclassified/rearranged/regrouped to conform to classification of current period, wherever necessary.

For and on behalf of the Board of Directors of
Tatva Chintan Pharma Chem Limited

Chintan N. Shah
Chairman and Managing Director
DIN : 00183618
Place : Vadodara, Gujarat, India
Date : 16 May 2026





Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



Date: 16 May 2026

Ref. No.: TCPCL/SEC/2026-27/00008

To,
The General Manager,
Corporate relationship department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001
Scrip Code: 543321

The Manager,
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex, Bandra(E),
Mumbai-400 051
Scrip Symbol: TATVA

Subject: Declaration pursuant to regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Dear Sir/Madam,

We hereby declare that the Statutory Auditors of the Company, M/s. NDJ & Co., Chartered Accountants, Surat (Firm Registration No. 136345W), have issued the Audit Report with unmodified opinion on the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended 31 March 2026.

This declaration is given in compliance with Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

You are requested to take the same on your records.

Thanking you,

Yours faithfully,
For Tatva Chintan Pharma Chem Limited


Ajesh Pillai
Chief Financial Officer

